Immunotherapy agents, such as immune checkpoint inhibitors (ICIs), act through different mechanisms compared to conventional chemotherapy and are characterized by unique patterns of response, such as hyperprogression (HPD), which refers to the paradoxical acceleration of tumor growth kinetics (TGK). In this regard, we sought to compare patterns of response to ICIs with respect to clinical and genomic features in a cohort of patients with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC). In our cohort, HPD was observed in 15.4% of patients. We report for the first time an association of HPD with both shorter progression free survival and overall survival in HNSCC. Importantly, in a multivariate Cox analysis, the presence of HPD remained an independent prognostic factor for survival. Primary site in the oral cavity and administration of ICI in the second/third setting were significant predictors of HPD in multivariate analysis. Comprehensive genomic profiling performed with OncoDEEP biomarker test revealed that gene amplification was more common in HPD patients.
Ensuring a Robust DNA Analysis and the Best Clinical Interpretation by Generating a High-Quality Data Set
OncoDEEP® Kit enables laboratories to achieve and consistently replicate high-quality sequencing data regarding coverage and sensitivity. Based on analytical performance this Whitepaper assesses the precision of OncoDEEP® Kit while measuring the repeatability and reproducibility. Combined...